IP Library › Granted Patent US 10,857,100
Granted Patent B2
US 10,857,100 · App. 16/172,171 · Granted Dec 8, 2020

Methods and compositions for administering an active agent to the pleura of a patient

Inventor: Glenn W. Laub (Princeton, NJ)
Assignee: TDL Innovations LLC
A61K9/122A61K33/18A61K47/36A61K9/0019A61K31/65A61K31/79A61K38/14A61K47/10A61K47/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,857,100
App. No.
16/172,171
Granted
Dec 8, 2020
Kind
B2
Abstract

A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and/or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and/or adhesion of the pleura.

Claims (25)

1. A method for administering an active agent to a parietal pleura and/or a visceral pleura of a patient comprising:

preparing a composition comprising a foamable liquid, a gas and the active agent;

introducing the composition into a pleural cavity of the patient defined by the parietal pleura and the visceral pleura, wherein upon introduction, the composition forms a foam; and

contacting the parietal pleura and/or the visceral pleura with the active agent and causing the fusion of the parietal pleura with the visceral pleura to reduce a volume of the pleural cavity,

wherein the foam does not form a cross-linked polymer network.

2. The method of claim 1 , wherein the active agent comprises one or more agents selected from the group consisting of: doxycycline, bleomycin, tetracycline, povidone iodine, talc, silica, and quinacrine.

3. The method of claim 1 , wherein the active agent comprises talc.

4. The method of claim 1 , wherein the foamable liquid comprises one or more copolymers of ethylene oxide and propylene oxide.

5. The method of claim 4 , wherein the copolymers of ethylene oxide and propylene oxide are one or more poloxamers.

6. The method of claim 5 , wherein the one or more poloxamers are selected from the group consisting of Poloxamer 407 (F127), Poloxamer 338 (F108), Poloxamer 188 (F68), and combinations thereof.

7. The method of claim 1 , wherein the gas is selected from the group consisting of air, oxygen, carbon dioxide, hydrogen, helium, argon, n-butane, n-pentane, fluorocarbons, hydrofluorocarbons, and combinations thereof.

8. The method of claim 7 , wherein the gas is selected from the group consisting of fluorocarbons, hydrofluorocarbons, and combinations thereof.

9. The method of claim 1 , wherein the foamable liquid is an aqueous solution.

10. The method of claim 1 , wherein the foam has a volume of about 10 to about 1000 times greater than the volume of the foamable liquid.

11. A method for administering talc to a parietal pleura and/or a visceral pleura of a patient comprising:

preparing a composition comprising:

(i) a foamable liquid comprising water and one or more copolymers of ethylene oxide and propylene oxide,

(ii) a fluorocarbon and/or hydrofluorocarbon, and

(iii) talc;

introducing the composition into a pleural cavity of the patient defined by the parietal pleura and the visceral pleura, wherein upon introduction, the composition forms a foam; and

contacting the parietal pleura and/or the visceral pleura with talc and causing the fusion of the parietal pleura with the visceral pleura to reduce a volume of the pleural cavity,

wherein the foam does not form a cross-linked polymer network.

12. The method of claim 11 , wherein the one or more copolymers of ethylene oxide and propylene oxide are one or more poloxamers.

13. The method of claim 12 , wherein the one or more poloxamers are selected from the group consisting of Poloxamer 407 (F127), Poloxamer 338 (F108), Poloxamer 188 (F68), and combinations thereof.

14. The method of claim 11 , wherein the foam has a volume of about 10 to about 1000 times greater than the volume of the foamable liquid.

Continuity (3)
Continuation 14674047 · Mar 31, 2015
Provisional Application 61973703 · Apr 1, 2014
Related Publication 20200129430A1 · Apr 30, 2020
Cited By (1)
US 12,410,293